samedan logo
 
 
 
spacer
home > pmps > spring 2009 > supply chain strategies
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supply Chain Strategies

In the pharmaceutical industry, companies face challenges ranging from margin pressures and rising costs to complex regulatory environments and growing competition – and increasingly, they are viewing the supply chain as a key ingredient in meeting those challenges successfully. With that in mind, the 2008-2009 ‘Global Pharma Industry Supply Chain & Tech Ops Study’ was conducted in order to develop a deeper understanding of the nature and evolution of the supply chain in the industry. The study involved 17 pharmaceutical and biotech companies across a variety of business segments and geographies, and was conducted under the guidance of a steering committee made up of major pharmaceutical manufacturers. By drawing on the experiences of industry participants, it aimed to provide a practical perspective that can help companies strengthen their ability to use the supply chain as a key driver of high performance.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Jay Welsh is a partner in Accenture’s Pharmaceutical & Medical Products Supply Chain practice out of the firm’s Boston office. He is the global lead for Accenture’s Clinical Supplies practice and Supply Chain Merger Integration practice. Jay is also the executive sponsor for the 2008 Pharmaceutical Industry Best Practices Study in Technical Operations & Supply Chain. Focusing on supply chain strategy, R&D, technical operations and merger integration, he has teamed up with both large and small pharma and biotech clients to reduce costs, increase revenues, improve customer service and drive strategic advantages within the marketplace.

spacer
Jay Welsh
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and SpyBiotech enter into a vaccine contract manufacturing agreement

[Noáin, Spain, October 26, 2020]3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement withSpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases.
More info >>

White Papers

The Rare Disease Patients Experience

When planning a clinical trial for a rare disease, it is important to have a holistic understanding of your patient population. You want to be aware of where your patients are coming from, and what it is like to walk in their shoes. These patients need your trial just as much as you need them; even from the earliest stages, conceptualize your rare disease trial as an altruistic relationship between the patient population and your study.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement